vs
Side-by-side financial comparison of LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) and DNA X, Inc. (SONM). Click either name above to swap in a different company.
LIFECORE BIOMEDICAL, INC. \DE\ is the larger business by last-quarter revenue ($31.1M vs $16.2M, roughly 1.9× DNA X, Inc.). DNA X, Inc. runs the higher net margin — -29.3% vs -32.1%, a 2.8% gap on every dollar of revenue. On growth, DNA X, Inc. posted the faster year-over-year revenue change (7.9% vs -4.5%). Over the past eight quarters, DNA X, Inc.'s revenue compounded faster (9.9% CAGR vs -0.1%).
LIFECORE BIOMEDICAL, INC. is a biomedical firm focused on developing and manufacturing high-quality hyaluronic acid-based biomaterials. It operates three core segments: medical application products, pharmaceutical solutions, and personal care ingredients, with main markets spanning North America, Europe and the Asia-Pacific, supplying to leading medical device, pharmaceutical and cosmetic brand partners.
LFCR vs SONM — Head-to-Head
Income Statement — Q2 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $31.1M | $16.2M |
| Net Profit | $-10.0M | $-4.8M |
| Gross Margin | 25.0% | 11.2% |
| Operating Margin | -9.9% | -24.5% |
| Net Margin | -32.1% | -29.3% |
| Revenue YoY | -4.5% | 7.9% |
| Net Profit YoY | -52.0% | -89.2% |
| EPS (diluted) | $-0.29 | $-4.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $31.1M | $16.2M | ||
| Q2 25 | — | $11.2M | ||
| Q1 25 | $35.2M | $16.7M | ||
| Q4 24 | $32.6M | $15.3M | ||
| Q3 24 | $24.7M | $15.0M | ||
| Q2 24 | — | $11.5M | ||
| Q1 24 | $35.7M | $9.1M | ||
| Q4 23 | $30.1M | $13.4M |
| Q3 25 | $-10.0M | $-4.8M | ||
| Q2 25 | — | $-7.5M | ||
| Q1 25 | $-14.8M | $458.0K | ||
| Q4 24 | $-6.6M | $-21.6M | ||
| Q3 24 | $-16.2M | $-2.5M | ||
| Q2 24 | — | $-6.6M | ||
| Q1 24 | $15.6M | $-2.9M | ||
| Q4 23 | $14.2M | $-1.4M |
| Q3 25 | 25.0% | 11.2% | ||
| Q2 25 | — | 7.6% | ||
| Q1 25 | 28.0% | 50.0% | ||
| Q4 24 | 34.0% | -1.2% | ||
| Q3 24 | 21.8% | 28.2% | ||
| Q2 24 | — | 25.8% | ||
| Q1 24 | 33.3% | 31.8% | ||
| Q4 23 | 33.0% | 38.1% |
| Q3 25 | -9.9% | -24.5% | ||
| Q2 25 | — | -60.2% | ||
| Q1 25 | -25.7% | 3.9% | ||
| Q4 24 | -6.0% | 55.3% | ||
| Q3 24 | -46.9% | -15.8% | ||
| Q2 24 | — | -56.2% | ||
| Q1 24 | -2.5% | -29.5% | ||
| Q4 23 | -4.9% | -9.3% |
| Q3 25 | -32.1% | -29.3% | ||
| Q2 25 | — | -66.8% | ||
| Q1 25 | -42.0% | 2.7% | ||
| Q4 24 | -20.2% | -141.6% | ||
| Q3 24 | -65.7% | -16.7% | ||
| Q2 24 | — | -57.5% | ||
| Q1 24 | 43.8% | -31.9% | ||
| Q4 23 | 47.2% | -10.1% |
| Q3 25 | $-0.29 | $-4.83 | ||
| Q2 25 | — | $-0.79 | ||
| Q1 25 | $-0.47 | $0.08 | ||
| Q4 24 | $-0.25 | $-116.99 | ||
| Q3 24 | $-0.53 | $-9.32 | ||
| Q2 24 | — | $-1.41 | ||
| Q1 24 | $0.42 | $-0.65 | ||
| Q4 23 | $0.39 | $-0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $18.9M | $2.1M |
| Total DebtLower is stronger | $136.0M | $5.1M |
| Stockholders' EquityBook value | $-10.5M | $-701.0K |
| Total Assets | $235.2M | $40.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $18.9M | $2.1M | ||
| Q2 25 | — | $2.0M | ||
| Q1 25 | $5.4M | $2.1M | ||
| Q4 24 | $9.5M | $5.3M | ||
| Q3 24 | — | $9.1M | ||
| Q2 24 | — | $9.6M | ||
| Q1 24 | — | $9.3M | ||
| Q4 23 | — | $9.4M |
| Q3 25 | $136.0M | $5.1M | ||
| Q2 25 | — | $2.9M | ||
| Q1 25 | $124.9M | $2.8M | ||
| Q4 24 | $111.3M | — | ||
| Q3 24 | $106.3M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $97.1M | — | ||
| Q4 23 | $92.9M | — |
| Q3 25 | $-10.5M | $-701.0K | ||
| Q2 25 | — | $-1.3M | ||
| Q1 25 | $2.2M | $-1.1M | ||
| Q4 24 | $15.4M | $-5.7M | ||
| Q3 24 | $-3.9M | $15.3M | ||
| Q2 24 | — | $17.5M | ||
| Q1 24 | $17.7M | $19.8M | ||
| Q4 23 | $1.4M | $22.4M |
| Q3 25 | $235.2M | $40.2M | ||
| Q2 25 | — | $36.1M | ||
| Q1 25 | $237.7M | $36.0M | ||
| Q4 24 | $255.4M | $39.7M | ||
| Q3 24 | $246.8M | $49.1M | ||
| Q2 24 | — | $45.9M | ||
| Q1 24 | $246.2M | $42.4M | ||
| Q4 23 | $245.8M | $56.0M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 56.05× | — | ||
| Q4 24 | 7.20× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 5.49× | — | ||
| Q4 23 | 65.35× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.8M | $-7.0M |
| Free Cash FlowOCF − Capex | $25.0K | — |
| FCF MarginFCF / Revenue | 0.1% | — |
| Capex IntensityCapex / Revenue | 5.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-16.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $1.8M | $-7.0M | ||
| Q2 25 | — | $-4.9M | ||
| Q1 25 | $1.2M | $-9.6M | ||
| Q4 24 | $-6.1M | $-4.5M | ||
| Q3 24 | $-613.0K | $-417.0K | ||
| Q2 24 | — | $-3.4M | ||
| Q1 24 | $-1.4M | $-168.0K | ||
| Q4 23 | $1.3M | $-351.0K |
| Q3 25 | $25.0K | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-4.3M | — | ||
| Q4 24 | $-8.6M | $-4.5M | ||
| Q3 24 | $-4.0M | $-554.0K | ||
| Q2 24 | — | $-3.4M | ||
| Q1 24 | $-7.8M | $-198.0K | ||
| Q4 23 | $-3.0M | — |
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -12.1% | — | ||
| Q4 24 | -26.3% | -29.6% | ||
| Q3 24 | -16.3% | -3.7% | ||
| Q2 24 | — | -29.8% | ||
| Q1 24 | -21.8% | -2.2% | ||
| Q4 23 | -9.9% | — |
| Q3 25 | 5.6% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 15.5% | — | ||
| Q4 24 | 7.5% | 0.1% | ||
| Q3 24 | 13.9% | 0.9% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | 17.8% | 0.3% | ||
| Q4 23 | 14.1% | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -20.97× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.09× | — | ||
| Q4 23 | 0.09× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LFCR
| Transferred At Point In Time | $26.6M | 85% |
| Transferred Over Time | $4.5M | 15% |
SONM
Segment breakdown not available.
